Evidence map›Paper›PMID 35460165›Full record

Trial reportClinical and translational science2022

The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.

Jatinder K Mukker, George Dukes, Max Tolkoff, Lisi Wang, Cristina Almansa, Susanna Y Huh, Mitsuhiro Nishihara, Diane Ramsden, Chunlin Chen

Open access · goldAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jatinder K MukkerTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
George DukesTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Max TolkoffTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Lisi WangTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Cristina AlmansaTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Susanna Y HuhTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Mitsuhiro NishiharaTakeda Pharmaceutical Company, Limited, Fujisawa, Japan.
Diane RamsdenTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Chunlin ChenTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Takeda (United States) · USTakeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trazpiroben is a dopamine D

Indexed as

Organic Anion TransportersRifampinAdultBiomarkersCross-Over StudiesDrug InteractionsHumansBiomarkersOrganic Anion TransportersRifampin

Identifiers

PMID35460165
PMCPMC9199876
OpenAlexW4224315025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.